Nyxoah is trading at $1.43, down -10.06%, with no confirmed company-specific catalyst identified for the September 29 decline.
- Nyxoah announced Liam Kelly’s appointment as CEO after the September 28 close, effective October 1; available reporting does not connect the appointment to the selloff.
- Healthcare was down 1.33%, offering sector context, but evidence does not establish it as the reason for Nyxoah’s move. Broader market indicators supplied were mixed and modest.